Share on StockTwits

Shares of Durata Therapeutics (NASDAQ:DRTX) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the stock, AnalystRatings.Net reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $19.38.

A number of research firms have recently commented on DRTX. Analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $21.00 to $24.00 in a research note on Tuesday, May 27th. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $19.00 to $23.00 in a research note on Tuesday, May 27th. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Durata Therapeutics from $14.00 to $15.00 in a research note on Tuesday, May 27th. They now have a “hold” rating on the stock.

Durata Therapeutics (NASDAQ:DRTX) opened at 16.26 on Wednesday. Durata Therapeutics has a 1-year low of $6.70 and a 1-year high of $17.20. The stock has a 50-day moving average of $15.03 and a 200-day moving average of $13.36. The company’s market cap is $433.2 million.

Durata Therapeutics (NASDAQ:DRTX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.02. On average, analysts predict that Durata Therapeutics will post $-2.39 earnings per share for the current fiscal year.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.